The findings about BA1106, a fully human monoclonal anti-CD25 antibody developed by Boan Biotech, a subsidiary of Luye Pharma Group, were published in Scientific Reports, which is a journal of the Nat...
Boan Biotech, a subsidiary of Luye Pharma Group, announced today that it has signed a Memorandum of Understanding with Merck, a world-leading science and technology company, under which the two partie...
Clinical trials of the drug in Europe and the U.S. are making good progressOctober 13, 2021, Shanghai -- Luye Pharma Group announced that the marketing authorization application for the Denosumab Inje...
Luye Pharma Group today announced that BA1105, a novel antibody developed by its subsidiary Boan Biotech, has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Prod...
September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
September 26, 2021, Boston, USA - Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific anti...
Boan Biotech has announced significant progress with LY-CovMab, a neutralizing antibody independently developedfor the treatment of COVID-19. LY-CovMab has been preliminarily validated for effectively...
Luye Pharma Group today announced that Boyounuo (Bevacizumab Injection), an oncology biologic developed in-house by its subsidiary Boan Biotech, has been approved by China’s National Medical Pro...
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) in Antibody Therapeutic...
博优诺®(Bevacizumab Injection), an anticancer drug developed by Boan Biotech, a subsidiary of Luye Pharma Group, was launched in China on June 5, 2021. The first product from Boan Biotech’s pipe...
Follow me
鲁公网安备37069102000284